drugset / Trial / NCT04188392

Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder

NCT04188392

Phase 4 Completed 6 enrolled Baylor College of Medicine
NaSingle-groupOpen-labelTreatment

Summary

This preliminary, open-label study assesses the feasibility of 34mg at bedtime for 6 weeks in Veterans with Posttraumatic Stress Disorder and insomnia.

Timeline

Start
2020-01-06
Primary completion
2021-10-27
Completion
2021-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimavanserin Small molecule 34 mg